

sk  
13/7  
--19. (New) The method of claim 13, further comprising multiple  
intradermal administrations every 4 weeks.

--20. (New) The method of claim 13, further comprising more than two  
intradermal administrations.--

REMARKS

Early and favorable consideration of this reissue application is respectfully  
requested.

Upon entry of this amendment, claims 1-20 will be pending in the application.  
New claims 3-20 have been added. New claim 3, 5, and 13 are supported at col. 4, lines  
62-63, of U.S. Patent No. 5,290,551 (the '551 Patent) which teach "autologous,  
cryopreserved, irradiated ... tumor cells." New claims 4, 10 and 18 find support at col 3,  
line 50, of the '551 Patent, which teaches that autologous melanoma cells are "irradiated at  
2500 R," a dose recognized in the art as a low radiation dose. Claims 6, 7, 14 and 15 find  
support at col 3, lines 40-41, of the '551 Patent, which teach that the vaccine composition  
can be injected "into 3 contiguous sites on the upper arms or legs." Claims 8 and 16 are  
supported at col. 5, lines 43-44, which teach that "tumors [are] excised from [the] patients  
before immunotherapy." Claims 9 and 17 are supported at col. 5, lines 4-6, teaching that  
tumor regression occurred "in lung and liver metastases" which are known in the art to occur  
only in stage four melanoma patients. Claims 11, 12, 19 and 20 are supported at col 3, lines  
32-33, and col 6, lines 14-17, which teach that the vaccine is "reinjecting every 4 weeks" and  
Example 4 (col 6, lines 34-64) which teaches that the vaccine is administered three times.

0303045-030600

As explained in the accompanying reissue declaration, the inventor and the patentee believes that the '551 patent may claim more than it had the right to claim. This reissue application and preliminary amendment is presented to address the prior art not cited during prosecution. More particularly, an Abstract authored by inventor David Berd (Tumor Inflammatory Response Induced by Immunization with Autologous Melanoma Cells Conjugated to Dinitrophenol (DNP); *Proc. Am. Assoc. Cancer Res.*, v. 30, March 1989) was published more than one year before the earliest filing date of the '551 patent. As explained in the accompanying declaration, this Abstract was not cited because the early publication date was not appreciated, nor was there any deceptive intent in omitting to cite the Abstract. The circumstances surrounding the error and lack of deceptive intent are set forth in the accompanying declaration.

### CONCLUSION

It is believed that the claims warrant allowance and such action is earnestly solicited. If the Examiner disagrees, or believes for any reason that the direct contact with applicant's attorney would advance prosecution of this application, he or she is invited to telephone at the number given bellow.

Respectfully submitted,



Nada Jain Ph.D.  
Registration No. 41,431  
Attorney for Applicants

DARBY & DARBY PC  
805 Third Avenue  
New York, N.Y. 10022  
(212) 527-7700